
5 things to know in life sciences: Week of Feb. 13, 2023

Economic News from RSM
by Justin Culbertson, Steve Kemler, David Stuart and Brian Winne
From reducing drug prices to artificial intelligence that provides real-time feedback for cardiac ultrasounds, here's what's happening in life sciences.
Each week we highlight five things you need to know in the life sciences industry. This week we explore promising developments in CRISPR genome editing, among other subjects.
This week we look at growing pharmaceutical manufacturing investment, the potential for a biotech recovery and more.
Justin has more than 10 years of experience serving publicly traded and privately held companies through technical accounting and financial reporting services. He focuses on clinical research organizations and similar service organizations in the constantly evolving life sciences industry. He has previously advised clients in the areas of new standard implementation, external audit, internal audit, risk management, mergers and acquisitions, process design and improvement, and internal and external financial reporting. He is also a member of RSM’s life sciences national industry leadership team.
In May 2021, Justin was selected as a senior analyst in RSM’s cutting edge industry eminence program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves.
Steve manages the Philadelphia market NetSuite team and provides NetSuite consulting services to a variety of clients in industries including life sciences, technology and wholesale distribution. Steve leads projects that require complex integrations, customizations and complex finance requirements.
As a member of RSM’s life sciences team, Steve consistently supports clients in the industry across the country. He also participates in the PACT MedTech series and is involved in multiple regional life sciences initiatives.
In May 2020, Steve was selected as a senior analyst in RSM’s cutting edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves.
David has more than eight years of corporate finance and capital markets experience supporting debt and equity transactions for various industries including technology, telecommunications, life sciences, renewable energy and consumer products. His experience includes negotiating and facilitating transaction closings for private equity, venture capital and financial institutions across North America.
In May 2020, David was selected as a senior analyst in RSM’s cutting edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves.
Brian Winne is a senior manager in RSM’s audit services focused on the life sciences industry. He was selected for the firm’s Industry Eminence Program in 2022 as a senior analyst covering the life sciences industry, working alongside the firm’s chief economist and other program participants to analyze trends and themes affecting life sciences companies in the middle market.
Brian has experience providing audit and business advisory services to his clients. He provides diverse accounting and compliance services to public and private clients in a variety of industries with a focus on biotech, life sciences and technology companies.